NCMAG111 Sunitinib advice document: January 2024

Posted on:


Document Type

NCMAG advice

Process guidance

Summary

Second line treatment of adult patients with poor or intermediate risk advanced/metastatic renal cell carcinoma who have received nivolumab in combination with ipilimumab as first line treatment. (Off-patent use)

Decision: Supported